IL22 and non-small cell lung carcinoma: Increased levels of STAT3-activating cytokines (e.g., IL6, IL11, IL22) and growth factors (e.g., HGF, leptin) are also observed in the serum and tumors of patients with NSCLC and promote persistent STAT3 activation via autocrine and paracrine mechanisms.